Literature DB >> 1362879

Salmonella, Campylobacter and Shigella in HIV-seropositive patients.

M R Nelson1, D C Shanson, D A Hawkins, B G Gazzard.   

Abstract

OBJECTIVE: To study the incidence, clinical features, treatment and outcome of patients with Salmonella, Shigella or Campylobacter infection.
DESIGN: Retrospective analysis.
SETTING: Two dedicated HIV units within a London teaching hospital.
METHODS: All patients with Salmonella, Shigella or Campylobacter infection were reviewed retrospectively by correlating the records of the gastrointestinal and microbiology departments with the computerized records of all HIV-positive patients attending the two clinics.
RESULTS: Between July 1985 and June 1991, 56 episodes of Salmonella, 37 of Campylobacter and eight of Shigella infection were documented in HIV-seropositive patients. Shigella was most likely to occur early in HIV disease, whilst patients with Campylobacter or Salmonella were more likely to have had a previous AIDS diagnosis. Septicaemica was most common in patients with Salmonella and was especially likely to occur in individuals with an AIDS diagnosis. Relapse of infection was common in patients with Salmonella, especially in those with low CD4 lymphocyte counts, those with an initial septicaemic illness and those not treated with ciprofloxacin.
CONCLUSIONS: Patients with Salmonella who have low CD4 lymphocytes counts and/or a septicaemic illness should be considered for life-long secondary prophylaxis with ciprofloxacin because of the high rate of relapse observed. Administration of zidovudine or cotrimoxazole as prophylaxis against Pneumocystis carinii pneumonia may prevent the development of salmonellosis: significantly fewer patients with this infection were taking these drugs than patients with Campylobacter.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362879     DOI: 10.1097/00002030-199212000-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  Selective culling of high avidity antigen-specific CD4+ T cells after virulent Salmonella infection.

Authors:  James M Ertelt; Tanner M Johanns; Margaret A Mysz; Minelva R Nanton; Jared H Rowe; Marijo N Aguilera; Sing Sing Way
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

Review 2.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

3.  Faecal alpha 1 antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals.

Authors:  D Sharpstone; A Rowbottom; M Nelson; B Gazzard
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

4.  Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease.

Authors:  D Islam; P K Bardhan; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

Review 5.  Gastrointestinal manifestations of HIV infection.

Authors:  D Sharpstone; B Gazzard
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

Review 6.  Small intestine pathogens in AIDS: conventional and opportunistic.

Authors:  J Koch; R L Owen
Journal:  Gastrointest Endosc Clin N Am       Date:  1998-10

Review 7.  Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.

Authors:  D Torre; F Speranza; R Martegani
Journal:  HIV Med       Date:  2005-03       Impact factor: 3.180

Review 8.  Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management.

Authors:  E N Janoff; P D Smith
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

9.  Disparities in severe shigellosis among adults - Foodborne diseases active surveillance network, 2002-2014.

Authors:  Lindsey S McCrickard; Stacy M Crim; Sunkyung Kim; Anna Bowen
Journal:  BMC Public Health       Date:  2018-02-07       Impact factor: 3.295

Review 10.  Severe acute diarrhea.

Authors:  Julia I Gore; Christina Surawicz
Journal:  Gastroenterol Clin North Am       Date:  2003-12       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.